trending Market Intelligence /marketintelligence/en/news-insights/trending/lH2PgKia7eGC8VFDNK8A7w2 content esgSubNav
In This List

Sage stock soars after depression drug meets main goal in phase 2 trial

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Sage stock soars after depression drug meets main goal in phase 2 trial

Sage Therapeutics Inc. said a phase 2 study of SAGE-217 in patients with moderate to severe major depressive disorder met its main goal.

In the trial conducted among 89 adult patients, the drug showed a statistically significant mean reduction from baseline in the Hamilton Rating Scale for Depression, or HAM-D, of 17.6 points, compared to 10.7 points for placebo.

The Hamilton Rating Scale for Depression is a multiple-item questionnaire used to provide an indication of depression.

At 15 days, 64% of the patients treated with SAGE-217 achieved remission, as measured by a score of 7 or less on the scale, versus 23% for placebo-treated patients.

The medicine was generally well-tolerated in the trial. The most common side effects recorded were headache, dizziness, nausea and somnolence.

The U.S. Food and Drug Administration had granted the treatment a fast-track designation in May.

Sage Therapeutics' stock was up 72.83% after the news to $158.83 as of 3:04 p.m. ET on Dec. 7.